Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies
26 mins; April 03, 2026
Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD
26 mins; April 02, 2026
FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD
15 mins; March 31, 2026
The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA
26 mins; March 31, 2026
Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD
27 mins; March 31, 2026
Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD
18 mins; March 31, 2026
FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
16 mins; March 30, 2026
Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD
15 mins; March 30, 2026
Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
30 mins; March 27, 2026
New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD
18 mins; March 27, 2026
T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD
42 mins; March 26, 2026
Utilizing Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD
9 mins; March 25, 2026
Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD
19 mins; March 25, 2026
ASCO GU 2026 Takeaways
12 mins; March 23, 2026
ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD
26 mins; March 20, 2026
ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD
11 mins; March 20, 2026
Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD
10 mins; March 18, 2026
Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role
29 mins; March 17, 2026
Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD
21 mins; March 13, 2026
Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum
30 mins; March 13, 2026
Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions
12 mins; March 11, 2026
Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care
30 mins; March 11, 2026
Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities
28 mins; March 10, 2026
Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI
18 mins; March 08, 2026
FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO
7 mins; March 06, 2026
Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
30 mins; March 06, 2026
Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD
8 mins; March 05, 2026
Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC
30 mins; March 03, 2026
Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD
20 mins; February 27, 2026
Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD
28 mins; February 27, 2026
Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma
30 mins; February 27, 2026
Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD
12 mins; February 26, 2026
Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD
10 mins; February 26, 2026
Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD
10 mins; February 26, 2026
Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data
28 mins; February 26, 2026
Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH
14 mins; February 25, 2026
Treatment Evolutions Affect First-Line Chemotherapy Selection in Metastatic Pancreatic Cancer: With Rachna T. Shroff, MD, MS, FASCO; and Kristen Spencer, DO
20 mins; February 25, 2026
Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD
12 mins; February 25, 2026
A Thoracic Oncologist’s Journey from Iran to Innovation: With Girindra Raval, MD; and Hossein Borghaei, DO, MS
44 mins; February 24, 2026
ASCO GU 2026 Preview
11 mins; February 24, 2026
Answering Common Questions About Chondrosarcoma Diagnosis and Management: With Hari Desphande, MD, and Philippos Costa, MD
27 mins; February 19, 2026
FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC: With Alexander I. Spira, MD, PhD, FACP, FASCO
6 mins; February 19, 2026
Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care
30 mins; February 18, 2026
Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD
16 mins; February 13, 2026
Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD
12 mins; February 11, 2026
“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments
29 mins; February 11, 2026
Targeted Therapies Take Center Stage for Estrogen Receptor–Positive Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
9 mins; February 10, 2026
Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE
17 mins; February 05, 2026
Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH
17 mins; February 04, 2026
Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS
24 mins; January 30, 2026
ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
12 mins; January 30, 2026
Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD
20 mins; January 30, 2026
Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD
14 mins; January 30, 2026
Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD
21 mins; January 30, 2026
Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
27 mins; January 30, 2026
Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD
8 mins; January 30, 2026
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
42 mins; January 29, 2026
ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
5 mins; January 29, 2026
Novel Targeted Agents Are Poised to Influence MPN Treatment Paradigm: With John O. Mascarenhas, MD
13 mins; January 29, 2026
Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate
49 mins; January 29, 2026
Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD
30 mins; January 28, 2026
Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics
28 mins; January 26, 2026
Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?
30 mins; January 22, 2026
Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights
27 mins; January 21, 2026
Hot Seat: Converging Lines in the Management of RAS-Altered Cancers
23 mins; January 21, 2026
Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD
5 mins; January 20, 2026
Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium
31 mins; January 20, 2026
Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms
29 mins; January 20, 2026
Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy
27 mins; January 20, 2026
Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
18 mins; January 16, 2026
Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life
21 mins; January 16, 2026
FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD
17 mins; January 15, 2026
FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD
9 mins; January 09, 2026
PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD
8 mins; January 07, 2026
Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO
26 mins; January 05, 2026
CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD
21 mins; December 31, 2025
FDA Approval of Enfortumab Vedotin/Pembrolizumab Redefines Perioperative Care for Cisplatin-Ineligible MIBC: With Christof Vulsteke, MD, PhD
8 mins; December 31, 2025
Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD
22 mins; December 29, 2025
MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD
24 mins; December 25, 2025
ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD
20 mins; December 22, 2025
Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD
7 mins; December 18, 2025
Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH
13 mins; December 17, 2025
ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
11 mins; December 16, 2025
Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD
33 mins; December 11, 2025
Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
23 mins; December 08, 2025
VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
8 mins; December 05, 2025
PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
33 mins; December 03, 2025
ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD
11 mins; December 02, 2025
Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS
4 mins; December 01, 2025
Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD
13 mins; November 30, 2025
Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD
6 mins; November 28, 2025
Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS
5 mins; November 27, 2025
Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD
20 mins; November 25, 2025
Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD
16 mins; November 24, 2025
Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD
7 mins; November 24, 2025
FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD
20 mins; November 20, 2025
Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD
14 mins; November 19, 2025
Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS
9 mins; November 18, 2025
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
27 mins; November 14, 2025
PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO
